Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib

Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib

Bibliographic Details
Main Authors:	Andrew J. Piper-Vallillo, MD, Daniel B. Costa, MD, PhD, MMSc, Marwa A. Sabe, MD, MPH, Aarti Asnani, MD
Format:	Article
Language:	English
Published:	Elsevier 2020-03-01
Series:	JACC. CardioOncology
Subjects:	cardiotoxicity epidermal growth factor receptor heart failure lung cancer osimertinib
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666087320300041

Similar Items

Osimertinib-Induced Cardiomyopathy
by: Shruti R. Patel, MD, et al.
Published: (2020-04-01)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
by: Zentaro Saito, et al.
Published: (2023-10-01)

Osimertinib-Induced Cardiotoxicity
by: Kartik Anand, MD, et al.
Published: (2019-12-01)

Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors∗
by: Dipesh Uprety, MBBS, et al.
Published: (2020-03-01)

Osimertinib-associated ashy dermatosis–like hyperpigmentation
by: Pattamon Lertpichitkul, MD, et al.
Published: (2020-02-01)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
by: Junjie GU, et al.
Published: (2021-11-01)

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
by: Molly S.C. Li, M.B.B.S., et al.
Published: (2024-04-01)

Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
by: Hiroshi Nokihara, et al.
Published: (2022-06-01)

Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature
by: Christopher Iriarte, MD, et al.
Published: (2022-11-01)

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
by: Yuki Takeyasu, MD, et al.
Published: (2024-02-01)

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
by: Leou Ismael Banla, MD, PhD, et al.
Published: (2023-10-01)

A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management
by: Mohammad Nawaf AlShatnawi, et al.
Published: (2022-12-01)

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2022-10-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)

Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib
by: Ji Young Park, et al.
Published: (2022-04-01)

Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report
by: Yuki Nukii, et al.
Published: (2019-02-01)

Osimertinib-associated erythema dyschromicum perstans–like eruption: A case series
by: Christina S. Oh, BA, et al.
Published: (2023-05-01)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
by: A.J. Piper-Vallillo, MD, et al.
Published: (2022-06-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
by: Jingran Ji, MD, et al.
Published: (2023-03-01)

Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
by: Oliver Gautschi, MD, et al.
Published: (2021-04-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

Mixed response to osimertinib and the beneficial effects of additional local therapy
by: Yuki Shinno, et al.
Published: (2019-04-01)

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer
by: Minehiko Inomata, et al.
Published: (2022-03-01)

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
by: Silvia La Monica, et al.
Published: (2019-05-01)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
by: Svetlana V. Odintsova, et al.
Published: (2020-07-01)

Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
by: Clayton P. Smith, MD, et al.
Published: (2023-03-01)

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
by: Xinyu von Buttlar, MD, MS, et al.
Published: (2021-06-01)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
by: Atsushi Osoegawa, MD, PhD, et al.
Published: (2021-07-01)

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib
by: Kensuke Kanaoka, et al.
Published: (2023-09-01)

Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell  Lung Cancer Patients with Acquired EGFR T790M Mutation
by: Yanfei GU, et al.
Published: (2022-12-01)

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
by: Beung-Chul Ahn, et al.
Published: (2021-07-01)

Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
by: Ling Zhang, et al.
Published: (2023-05-01)

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
by: Jie Wang, MD, PhD, et al.
Published: (2024-02-01)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
by: Silvia La Monica, et al.
Published: (2020-12-01)

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer
by: Matthew G. Field, et al.
Published: (2022-06-01)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
by: Qiuyue Ye, et al.
Published: (2023-05-01)

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report
by: Sunny Y. Lai, MD, et al.
Published: (2024-04-01)

An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment
by: Jie Liu, et al.
Published: (2024-01-01)